Navigation Links
SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production

AMSTERDAM, February 2 /PRNewswire/ -- SynCo Bio Partners B.V. today announced that it has signed two commercial manufacturing agreements with an undisclosed US biopharmaceutical company. Under the contract, SynCo will provide both process validation and GMP commercial manufacturing services to support the commercial launch of two separate biopharmaceutical products onto the US market.

SynCo has commenced with preparations for the manufacture of conformance lots in advance of its client's BLA filings, expected in late 2010, in anticipation of commercial manufacturing commencing in 2011.

The products are both recombinant proteins, to be produced in E. coli. These products will be manufactured in SynCo's large-scale GMP facility and take the tally of marketed products manufactured at its Amsterdam facilities to six, since SynCo's inception in 2000. SynCo has previously supported process development efforts for both products; an excellent example of how SynCo supports its clients' biopharmaceutical development programs from early stage to commercial supply.

Pierre Warffemius, CEO of SynCo Bio Partners said, "This news is a further example of how SynCo can offer a viable long-term manufacturing choice to its clients. SynCo has grown steadily over the last ten years in a very competitive market. The foundation of this growth has been our ability to form strong and mutually beneficial relationships with our clients. As a consequence, SynCo is one of few biopharmaceutical CMOs in the world with a recognized track record in both clinical and commercial manufacturing, providing financial stability that allows us to continuously invest in our facilities."

About SynCo Bio Partners B.V.

SynCo Bio Partners is a GMP-licensed bulk drug substance and final product CMO with clinical and commercial production experience in mammalian and microbial systems. This experience has been acquired by developing new production processes for a number of international clients and producing a wide variety of vaccines, recombinant proteins and live bacterial products in our state-of-the-art, GMP-licensed facilities since inception in 2000.

Focused solely on biopharmaceuticals, SynCo acts as a strategic, long-term partner delivering product on time to the highest quality standards. SynCo's team is committed to exceeding customer expectations, taking a truly collaborative approach to contract manufacturing.

For more information, please visit

SOURCE SynCo Bio Partners B.V.

SOURCE SynCo Bio Partners B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SynCo Bio Partners Completes Manufacture and Release of ActoGeniX Lead Product for Phase II Clinical Trials
2. SynCo Bio Partners Wins Best Contract Manufacturing Organization 2009 ViE Award
3. SynCo Bio Partners Increases its Capacities by Expanding its Quality Team
4. SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
5. SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
10. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... of IIROC on behalf of the Toronto Stock Exchange, ... release there are no corporate developments that would cause ... --> --> About Aeterna ... . --> Aeterna Zentaris is a ...
Breaking Biology Technology:
(Date:11/18/2015)... Nov. 18, 2015  As new scientific discoveries deepen ... and other healthcare providers face challenges in better using ... patients. In addition, as more children continue to survive ... adulthood and old age. John M. Maris, ... Hospital of Philadelphia (CHOP) . --> ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, Inc. ... the development and sale of broadly enabling, pressure cycling ... sciences industry, today announced it has received gross proceeds ... million Private Placement (the "Offering"), increasing the total amount ... or more additional closings are expected in the near ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
Breaking Biology News(10 mins):